Human papillomavirus vaccination: The policy debate over the prevention of cervical cancer-A commentary

Katherine E M Hoops, Leo B. Twiggs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The human papillomavirus (HPV) family causes a variety of benign, premalignant, and malignant lesions in men and women. HPV types 16 and 18 are responsible for causing 70% of all cases of cervical cancer each year. Recently, a vaccine that can prevent cervical cancer by protecting women from infection with the most common types of HPV has been made available. Following Food and Drug Administration approval and endorsement by the Centers for Disease Control and Prevention, it is the right and the duty of the state legislatures to implement vaccination programs. This vaccine, a vaccine for a sexually transmitted disease, has stirred a fierce debate. Religion and sexuality have dominated the discussion, and political calculations are inherent to the process; nonetheless, epidemiological analyses are also essential to the decision to mandate the HPV vaccine.HPV vaccine program implementation processes are at many stages in many states, and programs vary widely. Some provide information to families, whereas others allot a range of funding for voluntary vaccination. Virginia is, thus far, the only state to have enacted a mandate. This article discusses the various programs in place, the proposed legislation, and the debate surrounding the political process.

Original languageEnglish
Pages (from-to)181-184
Number of pages4
JournalJournal of Lower Genital Tract Disease
Volume12
Issue number3
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Papillomavirus Vaccines
Vaccination
Vaccines
Drug Approval
Human papillomavirus 18
Human papillomavirus 16
Sexuality
Religion
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Sexually Transmitted Diseases
Legislation
Infection

Keywords

  • Alphapapillomavirus
  • Cancer vaccines
  • Health policy
  • Papillomavirus vaccines
  • Politics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Human papillomavirus vaccination : The policy debate over the prevention of cervical cancer-A commentary. / Hoops, Katherine E M; Twiggs, Leo B.

In: Journal of Lower Genital Tract Disease, Vol. 12, No. 3, 01.07.2008, p. 181-184.

Research output: Contribution to journalArticle

@article{91086e7aad2e447d91101cdeaabf4917,
title = "Human papillomavirus vaccination: The policy debate over the prevention of cervical cancer-A commentary",
abstract = "The human papillomavirus (HPV) family causes a variety of benign, premalignant, and malignant lesions in men and women. HPV types 16 and 18 are responsible for causing 70{\%} of all cases of cervical cancer each year. Recently, a vaccine that can prevent cervical cancer by protecting women from infection with the most common types of HPV has been made available. Following Food and Drug Administration approval and endorsement by the Centers for Disease Control and Prevention, it is the right and the duty of the state legislatures to implement vaccination programs. This vaccine, a vaccine for a sexually transmitted disease, has stirred a fierce debate. Religion and sexuality have dominated the discussion, and political calculations are inherent to the process; nonetheless, epidemiological analyses are also essential to the decision to mandate the HPV vaccine.HPV vaccine program implementation processes are at many stages in many states, and programs vary widely. Some provide information to families, whereas others allot a range of funding for voluntary vaccination. Virginia is, thus far, the only state to have enacted a mandate. This article discusses the various programs in place, the proposed legislation, and the debate surrounding the political process.",
keywords = "Alphapapillomavirus, Cancer vaccines, Health policy, Papillomavirus vaccines, Politics",
author = "Hoops, {Katherine E M} and Twiggs, {Leo B.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1097/LGT.0b013e31815f98b5",
language = "English",
volume = "12",
pages = "181--184",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Human papillomavirus vaccination

T2 - The policy debate over the prevention of cervical cancer-A commentary

AU - Hoops, Katherine E M

AU - Twiggs, Leo B.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The human papillomavirus (HPV) family causes a variety of benign, premalignant, and malignant lesions in men and women. HPV types 16 and 18 are responsible for causing 70% of all cases of cervical cancer each year. Recently, a vaccine that can prevent cervical cancer by protecting women from infection with the most common types of HPV has been made available. Following Food and Drug Administration approval and endorsement by the Centers for Disease Control and Prevention, it is the right and the duty of the state legislatures to implement vaccination programs. This vaccine, a vaccine for a sexually transmitted disease, has stirred a fierce debate. Religion and sexuality have dominated the discussion, and political calculations are inherent to the process; nonetheless, epidemiological analyses are also essential to the decision to mandate the HPV vaccine.HPV vaccine program implementation processes are at many stages in many states, and programs vary widely. Some provide information to families, whereas others allot a range of funding for voluntary vaccination. Virginia is, thus far, the only state to have enacted a mandate. This article discusses the various programs in place, the proposed legislation, and the debate surrounding the political process.

AB - The human papillomavirus (HPV) family causes a variety of benign, premalignant, and malignant lesions in men and women. HPV types 16 and 18 are responsible for causing 70% of all cases of cervical cancer each year. Recently, a vaccine that can prevent cervical cancer by protecting women from infection with the most common types of HPV has been made available. Following Food and Drug Administration approval and endorsement by the Centers for Disease Control and Prevention, it is the right and the duty of the state legislatures to implement vaccination programs. This vaccine, a vaccine for a sexually transmitted disease, has stirred a fierce debate. Religion and sexuality have dominated the discussion, and political calculations are inherent to the process; nonetheless, epidemiological analyses are also essential to the decision to mandate the HPV vaccine.HPV vaccine program implementation processes are at many stages in many states, and programs vary widely. Some provide information to families, whereas others allot a range of funding for voluntary vaccination. Virginia is, thus far, the only state to have enacted a mandate. This article discusses the various programs in place, the proposed legislation, and the debate surrounding the political process.

KW - Alphapapillomavirus

KW - Cancer vaccines

KW - Health policy

KW - Papillomavirus vaccines

KW - Politics

UR - http://www.scopus.com/inward/record.url?scp=50549104271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549104271&partnerID=8YFLogxK

U2 - 10.1097/LGT.0b013e31815f98b5

DO - 10.1097/LGT.0b013e31815f98b5

M3 - Article

C2 - 18596458

AN - SCOPUS:50549104271

VL - 12

SP - 181

EP - 184

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 3

ER -